Oryzon Genomics, S.A. announced that Dr. Ana Limón has been appointed as Senior Vice President of Clinical Development and Global Medical Affairs. This appointment strengthens the company's permanent presence in the US as the company builds out strategic partnerships with US hospitals and research institutions to develop its pipeline and clinical programs. Dr. Limón's broad scientific and clinical research experience in hematology and oncology will be key in developing the company's clinical programs. She joins the company from Deciphera Pharmaceuticals.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.818 EUR | -0.22% | -3.61% | -3.71% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.71% | 112M | |
+19.41% | 45.51B | |
-8.62% | 38.52B | |
+38.65% | 38.13B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- ORY Stock
- News Oryzon Genomics S.A.
- Oryzon Genomics S.A. Appoints Ana Limón as Senior Vice President of Clinical Development and Global Medical Affairs